SRR12696732
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+0.500
- PROTEIN_SECRETION+0.400
- DNA_REPAIR+0.300
- MTORC1_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- GLYCOLYSIS+0.200
- HYPOXIA+0.200
- MYC_TARGETS_V1+0.200
Top 10 suppressed
- APICAL_SURFACE-0.300
- ALLOGRAFT_REJECTION-0.200
- APICAL_JUNCTION-0.200
- E2F_TARGETS-0.200
- G2M_CHECKPOINT-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
- NOTCH_SIGNALING-0.200
- PANCREAS_BETA_CELLS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.774 |
| 2 | MNG624 | — | — | 0.744 |
| 3 | BS_BJDNWMJH | EPN | EPN Tumor | 0.708 |
| 4 | MNG579 | — | — | 0.690 |
| 5 | SJEPD030250_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.681 |
| 6 | R266 | — | — | 0.677 |
| 7 | SRR10842375 | — | — | 0.674 |
| 8 | SRR23303753 | — | — | 0.669 |
| 9 | MDT-AP-1189 | Med | Medulloblastoma | 0.669 |
| 10 | SRR6013593 | — | cohortA1 | 0.668 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 0.500 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |